Systematic Review: Nicotinamide in Glaucoma—Human Evidence
A systematic review evaluated human evidence on nicotinamide and NAD-targeted strategies in glaucoma. Observational studies reported associations between glaucoma and altered circulating nicotinamide concentrations and systemic mitochondrial dysfunction. The authors consider the question of sustained neuroprotection or modification of glaucoma progression as open.
1. What the Research Says
PubMed, Scopus and the Cochrane Central Register of Controlled Trials were searched through August 2026; interventional, observational and mechanistic studies were included. Available studies were generally small and of limited duration, and the specific contribution of nicotinamide could not be isolated.
2. How It Fits Earlier Research
The new review is consistent with the earlier randomized crossover trial in which nicotinamide improved inner retinal function in glaucoma. Both leave open whether this can also modify the disease course over the long term. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover (2020)
3. Source
Nutrients: Nicotinamide Supplementation in Glaucoma: A Systematic Review of Human Studies. (2026-09-03)
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.